Abstract
The results of therapy with various doses and dose-schedules of cyclophosphamide of 146 patients with Burkitt's lymphoma are reported. Sixty-five patients were in stage I, 36 in stage II, 41 in stage III, and 4 in stage IV. Various doses in mg/kg used were 5, 10, 15, 20, 30, 40, 50, 60, 100, and 130; and administered either as i.v. infusion, or single i.v. injection or multiple (chronic) i.v. injection-schedule. In spite of the difficulty of follow-up of the patients thereby making an accurate summary of the long-term survivors impossible, evidence was presented of many patients surviving up to 5 years and longer. The study shows that: 1. complete and durable remissions could be achieved with cyclophosphamide; 2. long-term survivors are independent of the dosage or dose-schedules of the drug even in patients with stage III disease; 3. patients in stage IV disease did very poorly even with intensive chemotherapy; 4. patients can tolerate very high doses of cyclophosphamide.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call